Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07059611 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Apr 1, 2026 to Sep 1, 2026v4
  2. Start date: Nov 8, 2025 to Apr 1, 2026v3
  3. Start date: Sep 8, 2025 to Nov 8, 2025 Primary completion date: Sep 1, 2027 to Nov 1, 2027 · Completion date: Sep 1, 2029 to Nov 1, 2029v2 Show 2 more changesShow less
    • Primary completion date: Sep 1, 2027 to Nov 1, 2027
    • Completion date: Sep 1, 2029 to Nov 1, 2029
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a better job of killing cancer before surgery compared to chemotherapy alone.
Trial Details
NCT Number NCT07059611
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Replimune, Inc.
Conditions Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov